Home> News> Watch HARMONY’s journey toward enabling better and faster treatments for patients with Hematologic Malignancies

Watch HARMONY’s journey toward enabling better and faster treatments for patients with Hematologic Malignancies

January 16, 2020 12:41 - x 00, 0 - 00:00

We have created this short video explaining HARMONY’s long-term goals, the features that enable us to meet these goals and our achievements to date. 

Big Data analytics transform information into better outcomes for patients

A key feature of the HARMONY Alliance (established in 2017) is the HARMONY Big Data Platform, a unique tool that is transforming our approach to medical research across seven Hematologic Malignancies. The Big Data Platform uses machine learning techniques and advanced algorithms to transform large quantities of data from patient medical records into valuable knowledge, which can be utilized to improve patient care. View our infographic which explains how the Big Data Platform works.

The HARMONY Big Data Platform enables access to large volumes of detailed, high-quality data; as of December 2019, the Big Data Platform had identified a remarkable 45 000 patient datasets across seven Hematologic Malignancies. By applying Big Data analytics, our researchers can find answers to critical research questions that look to improve diagnosis rates and accuracy, optimize treatment decision-making, adress the unmet needs of patients and make progress in drug development across the seven Hematologic Malignancies.

Several ongoing research projects in these indications are already generating valuable results; new projects addressing additional research questions are also in the pipeline.

HARMONY is a public–private European partnership with more than 90 collaborating organizations including Partners, Associated Members and a Patient Cluster. Since its launch in 2017 HARMONY has continued to grow and gain momentum – read more about HARMONY’s vision.

Contact us to find out how you can become involved with HARMONY and participate in ongoing and future research projects!

The HARMONY Alliance is funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of more effective and safe medicines for patients. HARMONY has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No.116026. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

Receive the latest news. Click here to subscribe!